Sanofi pulls all filings after ODAC rejection of semuloparin
This article was originally published in Scrip
Sanofi has withdrawn its marketing authorisation application (MAA) for Mulsevo (semuloparin sodium) in Europe. The EMA says it has been formally notified by Sanofi of its decision, and that in its withdrawal letter, Sanofi had stated that it was withdrawing all applications globally "following comments by regulatory agencies".
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.